Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(359–386):E359-E386.
   PubMedGoogle Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182.
   Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672.
   PubMed Web of Science ®Google Scholar
• Joensuu H. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management. Drugs. 2012;72(15):1953–1963.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–1283.
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(25):3366–3373.
   Google Scholar
• Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(36):6129–6134.
   Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvantchemotherapy in HER2-positive early breast cancer: final analysis of theHERceptin Adjuvant (HERA) trial. Lancet. 2017 Mar 25;389(10075):1195-1205.
   Google Scholar
• Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14(8):741–748.
   Web of Science ®Google Scholar
• Conte P, Frassoldati A, Bisagni G, et al.  Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. Ann Oncol. 2018 Dec 1;29(12):2328-2333
   Google Scholar
• Earl HM, Hiller L, Vallier A-L, et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2-positive (+) early breast cancer (EBC): randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. J Clin Oncol. 2018;36(15_suppl):506.
   Web of Science ®Google Scholar
• Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(34):5685–5692.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Fraser J, Wildiers H, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol. 2018 sept 1;4(9):1199–1206.
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724–734.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783–1791.
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008 Dec;112(3):533–543.
   PubMed Web of Science ®Google Scholar
• Tiwari SR, Mishra P, Abraham J. Neratinib, A novel HER2-targeted tyrosine kinase inhibitor. Clin Breast Cancer. 2016 Oct;16(5):344–348.
   PubMed Web of Science ®Google Scholar
• Martin M, Bonneterre J, Geyer CE Jr, et al.  A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer. 2013 Dec;49(18):3763–3772
   Google Scholar
• Saura C, Garcia-Saenz JA, Xu B, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(32):3626–3633.
   Google Scholar
• Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(8):1301–1307.
   Google Scholar
• Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol. 2016;2(3):297–298.
   PubMedGoogle Scholar
• Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(3):404–412.
   Google Scholar
• Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22.
   Web of Science ®Google Scholar
• Jacobs SA, Robidoux A, Garcia JMP, et al. Abstract PD5-04: NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer. Cancer Res. 2016 Feb 15;76(4Supplement):PD5-04-PD5-04.
   Google Scholar
• 2 year HR+ ≤1 year from trastuzumab KM curve; 2 and 5 year iDFS (Neratinib Sept 2018 SmPC, 3004 study report).
   Google Scholar
• Rugo HS, Di Palma JA, Tripathy D, et al. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat. 2019 May;175(1):5–15.
   Google Scholar
• Gullick WJ, Berger MS, Bennett PLP, et al. Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer. 1987;40(2):207–212.
   PubMed Web of Science ®Google Scholar
• Uribe JM, Barrett KE. Nonmitogenic actions of growth factors: an integrated view of their role in intestinal physiology and pathophysiology. Gastroenterology. 1997;112(1):255–68.
   PubMed Web of Science ®Google Scholar
• McCole DF, Barrett KE. Decoding epithelial signals: critical role for the epidermal growth factor receptor in controlling intestinal transport function. Acta Physiol. 2009;195(1):149–159.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Perlemuter G, Malka D, et al. Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Rev Clin Oncol. 2008;5(5):268–278.
   Google Scholar
• Keefe DMK, Gibson RJ. Mucosal injury from targeted anti-cancer therapy. Support Care Cancer. 2007 May 1;15(5):483–490.
   Web of Science ®Google Scholar
• Barcenas C, Olek E, Hunt D, et al. Abstract P2-11-03: incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC): interim analysis from the multicenter, open-label, phase II control trial. Cancer Res. 2017;77(4 Supplement):P2-11–03-P2-11–03.
   Google Scholar
• Center for Devices and Radiological Health C for DE and R. Approved Drugs - FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer.
   Google Scholar
• European medicines agency - human medicines - nerlynx [Internet]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/hu
   Google Scholar
• A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer. https://clinicaltrials.gov/ct2/show/NCT01966471
   Google Scholar
• Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2–positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol. 2016;34(10):1034–1042.
   Web of Science ®Google Scholar
• Von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–131.
   PubMed Web of Science ®Google Scholar
• Howie LJ, Scher NS, Amiri-Kordestani L, et al. FDA approval summary: pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2018.
   Google Scholar
• Von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019 Feb 14;380(7):617–628.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Swain SM, Buyse M, et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. San Antonio Breast Cancer Symp. 2013;73(24):(S1–S03).
   Google Scholar
• Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–377.
   Web of Science ®Google Scholar
• Chia SKL, Martin M, Iwata H, et al. Abstract P1-13-03: effects of neratinib after trastuzumab-based adjuvant therapy in hormone receptor-positive HER2+ early-stage breast cancer: exploratory analyses from the phase III ExteNET trial. Cancer Res. 2018;78(4):(P1–13–03–P1–13–03).
   Google Scholar
• Wilks ST. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway. Breast. 2015;24(5):548–555.
   PubMed Web of Science ®Google Scholar
• Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2017;31, no. 18_suppl (June 20 2013) 5-5.
   Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013 Mar 9;381:805–816.
   PubMed Web of Science ®Google Scholar
• Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018 june 4;379:122–137.
   Web of Science ®Google Scholar
• Bulbul A, Araujo-Mino E, Dayao ZR. The conundrum of adjuvant HER2 treatment options. Front Oncol. 2018 May 30;8.
   Web of Science ®Google Scholar
• Tolaney SM, Barry WT, Guo H, et al. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). J Clin Oncol. 2017;35(15_suppl):511.
   PubMedGoogle Scholar
• Brandão M, Pondé NF, Poggio F, et al. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. Expert Rev Anticancer Ther. 2018;18(7):629–649.
   PubMed Web of Science ®Google Scholar